Laura Sepp-Lorenzino, EVP, Chief Scientific Officer at Intellia Therapeutics, Inc. (NTLA), sold 2,275 shares at $29.38 ($66K) on 2024-01-08, disclosed to the SEC on 2024-01-10.
Scheduled sale ($66k) by EVP, Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $28.66 | 1,608 | $46K | 70.2% |
| 2 | $29.38 | 667 | $20K | 29.8% |
| Total | $28.87 avg | 2,275 | $66K | 100% |
| Filing → |
| NTLA | SELL | 2023-01-06 | $339K | — | Filing → |
| NTLA | SELL | 2022-03-03 | $129K | — | Filing → |
| NTLA | SELL | 2021-09-01 | $30.0M | — | Filing → |